United Therapeutics is a biotechnology company focused on the development and commercialization of innovative therapies for chronic and life-threatening conditions. Its core products include treatments for pulmonary arterial hypertension and organ transplantation. The company operates primarily in the healthcare sector, with major revenue sources stemming from its pharmaceutical sales and partnerships in research and development.
The investment profile of United Therapeutics is more aligned with growth investors due to its focus on innovative therapies and potential for significant market expansion. The company shows promise in revenue growth, appealing to those looking for capital appreciation. Its profile suggests a medium to long-term investment horizon, with moderate liquidity, making it suitable for investors with a basic to advanced understanding of the market.
| Date | Before | After | Reason |
|---|---|---|---|
| 2026-11-10 | Hold | Buy | Strong fundamentals but mixed momentum signals. |
| 2026-11-06 | Buy | Hold | Weak momentum and high risk; hold for now. |
| 2026-10-21 | Hold | Buy | Strong performance but uncertain analyst signals. |
| 2026-10-17 | Buy | Hold | Weak momentum and high risk; hold for now. |
| 2026-10-11 | Hold | Buy | Positive momentum, but fundamentals show mixed signals. |
| 2026-10-09 | Buy | Hold | Weak momentum and high risk; hold for now. |
| 2026-10-07 | Hold | Buy | Stable fundamentals, but mixed momentum signals present uncertainty. |
| 2026-10-04 | Buy | Hold | Mixed performance; high risk with uncertain momentum. |
| 2026-10-02 | — | Buy | Strong recent performance supports bullish momentum. |
| Date | Analyst | Action | Target | Price Then |
|---|---|---|---|---|
| 2026-11-09 | H.C. Wainwright | Target Raised | — → 660 | 562.02 |
| 2026-11-05 | Wells Fargo | Target Raised | — → 703 | 608.49 |
| 2026-11-04 | Raymond James | Target Raised | — → 720 | 611.8031 |
| 2026-10-28 | J.P. Morgan | Target Lowered | 710 → 695 | 586.48 |
| 2026-10-26 | Cantor Fitzgerald | Target Raised | 700 → 850 | 590.5734 |
| 2026-10-22 | RBC Capital | Target Lowered | 708 → 697 | 577.0459 |
| 2026-10-20 | Raymond James | Target Raised | 685 → 717 | 564.15 |
| 2026-10-19 | UBS | Target Raised | 685 → 725 | 533.12 |
| 2026-10-15 | Goldman Sachs | Target Raised | 321 → 368 | 540.03 |
| 2026-10-14 | Jefferies | Target Raised | — → 728 | 543.4 |
| 2026-10-08 | RBC Capital | Target Raised | 677 → 708 | 533.8623 |
| 2026-10-01 | BTIG | Rating Upgraded | — → 728 | 541.89 |
| 2026-09-24 | Goldman Sachs | Update | — → 321 | 489.42 |
| 2026-08-06 | Morgan Stanley | Target Lowered | 516 → 515 | 519.01 |
| 2026-05-07 | Morgan Stanley | Target Lowered | 519 → 516 | 583.145 |
| 2026-05-07 | Wells Fargo | Rating Upgraded | — → 735 | 596.76 |
| 2026-05-07 | Wells Fargo | Rating Upgraded | — → 738 | 596.76 |
| 2026-04-10 | Morgan Stanley | Target Raised | 471 → 519 | 570.48 |
| 2026-04-10 | Raymond James | Update | — → 700 | 570.48 |
| 2026-03-12 | Cantor Fitzgerald | Target Raised | — → 625 | 541.6041 |
| 2026-02-26 | H.C. Wainwright | Target Raised | — → 600 | 508.4749 |
